Posted by AGORACOM-JC
at 9:32 AM on Tuesday, December 8th, 2020
Announced marketed public offering of 5,966,900 units of the Company at a price of $0.85 per Unit, for gross proceeds of $5,071,865
Each Unit is comprised of one common share of the Company and one-half of one common share purchase warrant of the Company
Each Warrant is exercisable for one Common Share at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering
TORONTO, ON , Dec. 8, 2020 – Avicanna Inc. (” Avicanna “, or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce the closing of its previously announced marketed public offering of 5,966,900 units (the ” Units “) of the Company at a price of $0.85 per Unit, for gross proceeds of $5,071,865 (the ” Offering “). Each Unit is comprised of one common share of the Company (each a ” Common Share “) and one-half of one common share purchase warrant of the Company (each full warrant, a ” Warrant ” and collectively the ” Warrants “). Each Warrant is exercisable for one Common Share at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering.
The Offering was conducted on a “best efforts” basis by a syndicate of agents led by Echelon Wealth Partners Inc., as lead agent and sole-bookrunner, and including Beacon Securities Limited and Canaccord Genuity Corp. (collectively, the ” Agents “).
Aras Azadian , CEO of Avicanna, commented: “The completion of our first prospectus offering and substantial capital raise since our IPO is a confirmation of the on-going support from our existing and new shareholders during a difficult time in the market. This also coincides with further cost reductions and with the launch of our medical products and several other commercial initiatives across several markets where we intend to use the use the proceeds of this raise to pave the way to sustainability and profitability.”
The Company has granted the Agents an option, exercisable in whole or in part, at the sole discretion of the Agents, at any time for a period of 30 days from and including the closing of the Offering, to purchase from the Company up to an additional 15% of the Units sold under the Offering, on the same terms and conditions of the Offering to cover over-allotments, if any, and for market stabilization purposes (the ” Over-Allotment Option “). The Over-Allotment Option may be exercised by the Agents to purchase additional Units, Common Shares, Warrants or any combination thereof.
The Company intends to use the net proceeds of the Offering for product development, working capital and general corporate purposes.
The securities described in this press release have not been and will not be registered under the United States Securities Act of 1933 , as amended (” U.S. Securities Act “) or any state securities laws. Accordingly, the securities may not be offered or sold in the United States (as such term is defined in Regulation S under the U.S. Securities Act) or to, or for the account or benefit of, a U.S. person (as such term is defined in Regulation S under the U.S. Securities Act) except pursuant to transactions exempt from registration under the U.S. Securities Act and under the securities laws of any applicable state. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States .
About Avicanna Inc.
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:
Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.
With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.
Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta , Colombia . Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020 , Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia .
Stay Connected
For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected] .
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by the Company, including satisfaction of regulatory requirements in various jurisdictions, exercise of the Over-Allotment Option and the use of proceeds from the Offering.
Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .
Posted by AGORACOM-JC
at 9:27 AM on Tuesday, December 8th, 2020
Will be presenting at Alpha Bronze Virtual Town Hall on Wednesday, December 9, 2020 at 12:00 PM EST.
Mr. Bernard Tourillon, Chief Executive Officer of HPQ Silicon, will give an overview of the Company and its growth plan. HPQ Silicon’ objective is to produce high-value speciality Silicon products using new technologies to reduce energy consumption. Mr. Tourillon will respond to Investors questions thereafter.
December 8, 2020 / Alpha Bronze, LLC (“Alpha Bronze”), is pleased to announce that HPQ Silicon Resources Inc. (“HPQ” or “the Company”) (TSXV:HPQ)(OTC PINK:URAGF), a Canadian Innovative Silicon Solutions Provider, will be presenting at Alpha Bronze Virtual Town Hall on Wednesday, December 9, 2020 at 12:00 PM EST.
Mr. Bernard Tourillon, Chief Executive Officer of HPQ Silicon, will give an overview of the Company and its growth plan. HPQ Silicon’ objective is to produce high-value speciality Silicon products using new technologies to reduce energy consumption. Mr. Tourillon will respond to Investors questions thereafter.
HPQ Silicon Resources is a Canadian Innovative Silicon Solutions Provider. Silicon (Si) is one key materials for the decarbonization of the economy and the Renewable Energy Revolution. HPQ is building a portfolio of silicon-based products using innovative, scalable processes. The aim is to produce high-value speciality Silicon products using technologies that will reduce energy consumption, GHG’s, and carbon footprint. Working with PyroGenesis Canada, a high-tech company, HPQ is developing the PUREVAP™ “Quartz Reduction Reactors”, an innovative process, which will permit the one step transformation of quartz (SiO2) into high purity silicon at reduced costs. HPQ Silicon is listed on the TSXV under the symbol “HPQ”. For more information: https://hpqsilicon.com
About Alpha Bronze
Founded in 2013, Alpha Bronze is an investor relations firm based in New York. Alpha Bronze is dedicated to the delivery of top-tier strategic services that encompass IR, capital markets navigation, and corporate communications. The firm has an extensive experience working with emerging growth companies, in the clean-tech, life sciences, consumer and mining sectors. Alpha Bronze’s aim is to increase awareness for its clients among the US investment community. For more info: https://www.alphabronzellc.com
Posted by AGORACOM-JC
at 9:23 AM on Tuesday, December 8th, 2020
Announced today that at the Company’s Board of Directors’ meeting on December 7th, 2020, it was formally approved to move forward with the strategic decision to file an application to list its common shares on the NASDAQ Stock Exchange over the next several days.
NASDAQ is the second largest exchange by market capitalization worldwide, and is home to many of the world’s best technology companies.
Company has engaged Nelson Mullins Riley & Scarborough LLP as its US legal counsel to process the NASDAQ listing, and the Company’s external Canadian legal counsel will provide the required oversight during this process.
PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQB: PYRNF) (FRA: 8PY), (the “Company”, the “Corporation” or “PyroGenesis”) a Company that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to announce today that at the Company’s Board of Directors’ (the “Board”) meeting on December 7th, 2020, it was formally approved to move forward with the strategic decision to file an application to list its common shares (“Shares”) on the NASDAQ Stock Exchange (“NASDAQ”) over the next several days. NASDAQ is the second largest exchange by market capitalization worldwide, and is home to many of the world’s best technology companies.
The Company has engaged Nelson Mullins Riley & Scarborough LLP as its US legal counsel to process the NASDAQ listing, and the Company’s external Canadian legal counsel will provide the required oversight during this process.
“We are pleased to announce today another significant step towards ultimately enhancing shareholder value,” said Mr. P. Peter Pascali, CEO and Chair of PyroGenesis. “The United States has the largest capital market in the world and, as such, a NASDAQ listing has always been on our radar as one of the many strategies to execute as part of our long-term vision for the Company. On the back of our recent achievements, and our successful uplisting to the Toronto Stock Exchange (“TSX”), the Board decided that the timing was right to proceed with this application. After discussions with our US legal counsel, and a representative of NASDAQ, it was confirmed that the Company meets the standard requirements for a listing. However, there still remains a rigorous application procedure which the Company must pass before a final listing is granted. The listing, barring any delays or objections, is expected before the end of Q1 2021.”
There will not be a concurrent financing associated with this listing nor will there be a reverse stock split.
“A NASDAQ listing is a natural next step for the Company,” said Ms. Rodayna Kafal, VP IR/Comms and Strategic BD. “We believe a NASDAQ listing should, amongst other things, (i) provide additional opportunities to attract institutional and retail investors, thus allowing the Company to further broaden its investor base, and (ii) increase the visibility and credibility of the Company worldwide thereby attracting additional sales, partnerships, and M&A opportunities.”
In advance of an anticipated listing on NASDAQ, PyroGenesis will, over the next several days, formally file an application to list on NASDAQ. Shortly thereafter, the Company will file a 40-F registration statement with the United States Securities and Exchange Commission (SEC). The listing of the Company’s Shares on NASDAQ remains subject to the approval of the exchange, and the satisfaction of all applicable listing and regulatory requirements. The Company will continue to maintain the listing of its Shares on the TSX and, subsequent to a successful listing, would trade on both exchanges under the ticker symbol “PYR”.
About PyroGenesis Canada Inc. PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com.
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com.Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.
SOURCE PyroGenesis Canada Inc.
For further information please contact: Rodayna Kafal, Vice President, IR/Comms. and Strategic BD Phone: (514) 937-0002, E-mail: [email protected]
Posted by AGORACOM-JC
at 8:12 AM on Tuesday, December 8th, 2020
Verified Self Sovereign Identity, together with a complete end-to-end issuance and verification health credentials ecosystem, ensures individuals have full privacy and control of personal healthcare data, including vaccination records, so they can securely start returning back to public life, freely.
Announced the formation of a consortium of industry leaders that will empower people to start getting back to the activities, people and places they have been missing in their lives.
The consortium has developed an integrated solution that enables healthcare issuers, individuals and verifiers to have a digital COVID-19 verifiable identity healthcare credential that is secure, user managed and controlled to ensure privacy, transportability and ease of use.
This solution supports the foundation for the acceptance of digital Healthcare Passports.
TORONTO, ON and GIBRALTARDecember 8, 2020 / The KABN Network, together with KABN Systems NA Holdings Corp. (CSE:KABN) (the “Company” or “KABN North America”), a Canadian fintech company that specializes in continuous online identity verification, management and monetization in Canada and the US, through its biometrically and identity verified Self Sovereign Identity platform, Liquid Avatar (www.liquidavatar.com), today announces the formation of a consortium of industry leaders that will empower people to start getting back to the activities, people and places they have been missing in their lives. The consortium has developed an integrated solution that enables healthcare issuers, individuals and verifiers to have a digital COVID-19 verifiable identity healthcare credential that is secure, user managed and controlled to ensure privacy, transportability and ease of use. This solution supports the foundation for the acceptance of digital Healthcare Passports.
This consortium initially includes the Lumedic Exchange, to power the healthcare credential ecosystem; Loop Insights (MTRX), a leader in automatic contact tracing; The Campus Agency, to support on campus programs at over 2,000 US Colleges and Universities; and TripXpertz, an organization that works with over 1,000 travel and tourism boards, airlines, wholesalers and resorts, together with Liquid Avatar’s Self Sovereign Identity platform to empower the worldwide Healthcare industry to issue Identity-based Verifiable Credentials through a secure, effective and cost-efficient ecosystem.
This ecosystem will allow qualified Health Professionals with the ability to issue a Verifiable Credential that enables venues and other facilities to verify both the issued credential and the known user in real-time to grant access and / or services. This partnership built on a Trust over IP (TOIP) open standards framework, and the World Wide Web Consortium’s (W3C) specifications for decentralized identifiers for credential management, can power interoperable COVID-19 vaccination and other verifiable credentials across a host of user managed and controlled digital wallets and applications. This process can be used for multiple use cases such as Education, Workplaces, Tradeshows, Healthcare, Sporting Events, Concerts, Entertainment, Travel, Places of Worship, Senior Living, and other facilities, venues and locations and opens the door to further opportunities for commercial and consumer opportunities.
Liquid Avatar’s Self Sovereign Identity (SSI) platform, which includes user biometric validation and a bank-grade verified identity credential, is available to consumers at no cost. Liquid Avatar enables users to verify and manage their identity and access credentials in a cloud-based, biometrically-secure application. Users have complete control over their digital assets (like wallets, passwords and more), identity, and data through easy to use avatars that can be shared, on a permission-basis with others. The COVID-19 Verifiable Healthcare Credential combines healthcare data with the user’s biometrically verified identity credential. When a request is made by a Verifier, the User has a choice of which attributes are shared, creating a private verification transaction between themselves and a verifier. While much of the technology and services are already in place, the launch of the healthcare credential pilot is expected to take place in the first quarter of 2021 to coincide with the expected release of the COVID-19 widespread vaccination program.
This program will not only be able to verify identity credentials for the Covid-19 vaccines, diagnostic and antibody testing, but will also be able to support a wide range of immunizations and healthcare records.
“We want to empower users to return to public life and the things they once did freely, pre-COVID-19, with ease and continued safety, with this and future credentials,” said David Lucatch, CEO of KABN. “Our goal is to help get everyone back to life as efficiently and effectively as possible, so a sense of “normality” can be reestablished. Liquid Avatar and the ecosystem, together with this amazing group and a growing list of partners, will potentially enable businesses, schools, entertainment venues, and more do the normal things that they do and give users the power to engage with them as they did before the pandemic changed our lives.”
Healthcare issuers and individuals will be granted access to the system at no cost. Verifiers wishing to access the system will be charged a nominal subscription and micro-payment per verification, making it very cost efficient and effective to use the system for small and medium sized enterprises all the way up to major airlines, venues and facilities. The partners are committed to making the services affordable to all parties, so that everyone can get back to their everyday lives.
The KABN Network is working with leading industry partners to provide a safe and effective ecosystem that supports the issuance, ownership and verification of these verified identity and access credentials and is proud to be working with the following partners at the outset of this announcement covering a wide range of technologies, issuer, consumer and verification engagement, with additional partners to be named as the program grows.
Trust over IP Foundation (ToIP)
As a member of the Trust over IP Foundation (www.trustoverip.org) steering committee, The KABN Network is committed to the organization’s open-standard framework and tech stacks. ToIP recently released its Covid-19 Credentials Initiative (“CCI”) Governance Framework for public review.
“Trust over IP offers an important new model for how to assemble the pieces that create working and reliable digital trust ecosystems. We are very excited to see momentum growing for real-world cases where the model is being used to make people’s digital lives simpler and better. This includes the KABN Network becoming part of the Lumedic Exchange,” said John Jordan – Executive Director of the Trust over IP Foundation. “We hope to see this momentum continue, and more organizations using the Trust over IP model to create solutions that benefit individuals and businesses.”
Lumedic Exchange
The KABN Network, as a founding partner, is working with the Lumedic Exchange (www.lumedic.io), an open-standards, decentralized framework for the healthcare industry giving patients greater control over their health data.
Chris Ingrao, Chief Strategy Officer of Lumedic, a US-based Health technology company, part of Providence Health Systems ecosystem, comments: “Lumedic recently launched the Lumedic Exchange, the first healthcare ecosystem of its kind dedicated solely to community-driven standards development for patient-intermediated information exchange using verifiable credentials, to support secure exchange of vaccination information.”
Loop Insights, Inc.
Powering professional sports, entertainment, collegiate and other venues and facilities with Automatic Contract Tracing, Loop Insights, Inc. (www.loopinsights.ai) (MTRX) has developed a fully managed contactless check-in platform that securely transfers contact information and triggers real-time notifications at scale.
“The success Loop has had with our recent NCAA sporting events using our venue tracing and management tools, only reinforces the need for a unified verifiable credential that consumers and businesses can trust. Working with KABN and Liquid Avatar and their digital identity platform will provide our customers – and ultimately consumers – with the level of trust required to provide personal information such as COVID testing results, vaccination proof, payment, and other sensitive personal information required in today’s changing landscape. We are thrilled to be one of the first partners to work with KABN and Liquid Avatar on an end to end solution that will provide this safety, security, and peace of mind required to protect consumers looking to return to a new way of life where mobile devices and personal information will be at the forefront of nearly every interaction”, Rob Anson, President and CEO Loop Insights.
The Campus Agency
With reach to over 2,000 US College and University campuses and over 1.5 Million Gen Z students, alumni and families, The Campus Agency (www.thecampusagency.com) has been supporting innovative direct to student and online marketing programs for over 40 years.
“We are really excited to be working with KABN and Liquid Avatar and be a member of this consortium. COVID-19 has impacted the lives of students and faculty on college campuses in such a major way, and we are looking forward to being part of a solution that provides campus communities with the tools and resources they need to return to their way of lives, safely and securely,” Chris Nyland, Chief Operating Officer, The Campus Agency
TripXpertz
Powering over 1,000 travel and government tourism boards, airlines, travel wholesalers and resorts in US, Canada, Mexico, the Caribbean and around the world, to more effectively reach their intended travel audiences with end to end travel marketing management, booking and analytics solutions TripXpertz (www.tripxpertz.com) is changing the way the travel industry reaches travelers and how travelers can receive better value from their travel experiences.
“Our Priority Protection Passport program is aimed at restoring consumer confidence and trust in travelling again and piece-of-mind while away,” says Brad Miron, CEO of TripXpertz. “This partnership gives us, and our multiple program stakeholders, the ability to verify an individual’s identity with certainty, while maintaining security and privacy – In the context of Priority Protection Passport, Liquid Avatar and the capabilities of the Verifiable Identity Healthcare Credentials are foundational to what we must deliver to attract, assure and welcome back tourists to destinations.”
For more information on the program and / or how to become a consortium partner or participant, please visit www.liquidavatar.com
KABN Systems NA Holdings Corp. through its wholly owned subsidiary KABN Systems North America Inc. focuses on the verification, management and monetization of Self Sovereign identity, empowering users to control and benefit from the use of their online identity. The KABN proprietary technology suite includes 4 key products:
Liquid Avatar is a verified Self Sovereign Identity platform empowers users to create high quality digital icons representing their online personas. These icons, in conjunction with KABN ID, allow users to manage and control their digital identity and Verifiable Access and Identity Credentials, and to use Liquid Avatars to share public and permission based private data when they want and with whom they want. www.liquidavatar.com
KABN ID is an Always On, biometric and blockchain based digital identity validation and verification platform allowing users to continuously and confidently prove themselves throughout the online community.
KABN Systems NA Holdings Corp. is publicly listed on the Canadian Securities Exchange (CSE) under the symbol “KABN” (CSE:KABN)
If you have not already joined our mailing list, and would like to receive updates on KABN Systems NA Holdings Corp., please click here to join!
The Trust over IP Foundation is defining a complete architecture for Internet-scale digital trust that combines both cryptographic trust at the machine layer and human trust at the business, legal, and social layers.
Lumedic is a health information logistics company that helps healthcare stakeholders optimally cooperate throughout the administrative ecosystem. The Lumedic platform includes a suite of healthcare interoperability solutions that harmonize action and relieve friction across revenue cycle management, clinical operations, and patient engagement. Lumedic leverages AI, distributed ledgers, design thinking, and open standards to advance the state of healthcare technology and deliver greater health, safety, and wellbeing for patients and communities.
Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.
With reach to over 2,000 US College and University campuses and over 1.5 Million Gen Z students, alumni and families, The Campus Agency (www.thecampusagency.com) has been supporting innovative direct to student and online marketing programs for over 40 years.
TripXpertz is Toronto-based marketing technology (“MarTech”) company with a 20 year track-record of delivering new monetization paths and superior traveller acquisition and conversion for tourist boards and travel providers globally. The company provides highly targeted, “zero risk”, pay-of-performance campaigns backed by rich engaging destination content that drives awareness and customer conversions at a fraction of industry norm acquisition costs.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities under the KABN Financing in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Forward-Looking Information and Statements
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, information concerning the ability of the Company to generate revenues, roll out new programs and to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.
By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.
Posted by AGORACOM-JC
at 7:28 AM on Tuesday, December 8th, 2020
Empower’s KAI Medical Laboratory Is A Priority Testing Partner That Is Expected To Participate In Significant Programs Aimed At Opening Up Key Travel and Hospitality Industries
Announced the signing of a Memorandum Of Understanding (“MOU”) with SimpliFlying, the world’s leading aviation marketing consulting firm, to provide COVID-19 testing support for airlines and travel bubbles.
SimpliFlying has been consulting to airlines for over a decade and is one of the largest in the world, having worked with over 100 major clients including airlines, OEMs and airports globally with clients that include American Airlines, Turkish Airlines, LATAM Airlines, Airbus, Boeing, Bombardier and Toronto Pearson Airport.
SimpliFlying also solves complex operational issues facing the airline and tourism industry, working with large hotel groups such as Intercontinental and others.
VANCOUVER, BC / December 8, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the Southwest United States, a telemedicine platform and a leading medical diagnostics laboratory is pleased to announce the signing of a Memorandum Of Understanding (“MOU”) with SimpliFlying, the world’s leading aviation marketing consulting firm, to provide COVID-19 testing support for airlines and travel bubbles.
SIMPLIFLYING IS A TRUSTED NAME TO AIRLINES, AIRPORTS AND HOTEL GROUPS
SimpliFlying has been consulting to airlines for over a decade and is one of the largest in the world, having worked with over 100 major clients including airlines, OEMs and airports globally with clients that include American Airlines, Turkish Airlines, LATAM Airlines, Airbus, Boeing, Bombardier and Toronto Pearson Airport.
SimpliFlying also solves complex operational issues facing the airline and tourism industry, working with large hotel groups such as Intercontinental and others.
SIMPLIFLYING LAUNCH OF “SIMPLI TESTED” RECEIVES EARLY PRAISE AS ONE OF THE MOST COMPREHENSIVE APPROACHES SO FAR
With the Coronavirus Pandemic wreaking havoc on the global airline and tourism industry, the work of SimpliFlying has become more important than ever in helping solve how airlines, airports, cruise lines, hotels and tourism will safely get back to operations. SimpliFlying is working closely with major international airlines and major Canadian airlines on “Travel Bubbles” and “Tourism Bubbles” that involve testing protocols using PCR tests, rapid PCR, rapid antibody and rapid antigen tests throughout the travel supply chain.
To this end, SimpliFlying has just launched SimpliTested to highlight and support the needs of key industries around the globe, in partnership with FDA and CE approved testing providers, reliable labs and cutting-edge exposure notification applications. The initiative has already received early praise from the media:
EMPOWER TO PROVIDE MARKET LEADING COVID-19 TESTING SUPPORT AND TRAVELLER ACCESS TO LABS ACROSS NORTH AMERICA
Shashank Nigam, Founder & CEO of SimpliFlying stated “To kickstart travel, airlines and airports need to offer easy access to labs that can turn around accurate test results in a speedy manner. SimpliFlying’s partnership with Empower Clinics will bring access to labs all across North America to support travellers.”
Empower will provide COVID-19 testing support with our most recent products launched in the United States including:
Empower will also provide additional critical functionality to support the strategic consulting work provided by SimpliFlying to airlines and the hospitality industry, including the ability to support onsite collection operational processes at airports, hotels and cruise lines.
Moreover, Empower has the ability to provide additional support for a variety of solutions that may require and are capable of delivering critical elements such as contact tracing technology.
Finally, both Companies intend to lead education and proof of concept with the goal of eliminating 14-day quarantine requirements upon return to Canada. Having structured policies and testing protocols to confirm that travellers are negative for the COVID-19 virus has the potential to significantly open up travel limitations.
Steven McAuley, Chairman and CEO of Empower stated “Once I made the connection with Shashank the SimpliFlying Founder & CEO, I knew right away that a partnership needed to be created given how complementary our companies are to each other. Shashank and team have impressed me with their technical knowledge of the airline, tourism and hospitality industries, they understand exactly what is required to get these key industries back on track, back to work, to get consumers traveling again. Together, utilizing the operational and testing protocols coming to market right now from our wholly owned subsidiary KAI Medical Laboratory, has the potential to make a meaningful and lasting impact on these global industries.”
PARTNERSHIP FURTHER SOLIDIFIES KAI MEDICAL FOOTHOLD IN COVID-19 TESTING SPACE
KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.
As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including airlines, hotels, cruise lines and movie & television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.
ABOUT SIMPLIFLYING
SimpliFlying is one of the world’s leading aviation marketing consulting firms with a team remote-based in Singapore, Spain, UK and Canada, with the ability to provide airlines with a global and a 24/7 presence. Since 2009, the company has worked with an enviable list of aviation brands and built a unique work culture that appeals to the disruptors in the industry. The team is energetic and brimming with ideas on how to make airlines remarkable. These are ideas based on working with over 100 clients over the past ten years.
ABOUT EMPOWER
Empower provides body and mind wellness for more than 165,000 patients through its clinics in the United States, a telemedicine platform and a world-class medical diagnostics laboratory in Texas. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across the U.S. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ABOUT KAI MEDICAL LABORATORY
Our mission is to improve healthcare through science and innovative quality diagnostics, providing value added services, accuracy, and consistency. Operating with an unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to higher standards for patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas). KAI Medical Laboratory has completed clinical trials on novel COVID-19 testing protocols and assisted in supporting FDA and Health Canada submissions.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the future potential success of Kai Medical Laboratory, Sun Valley’s future potential; whether a definitive agreement will be reached with SimpliFlying; or the ability of Empower’s wholly owned subsidiary Kai Medical Laboratory to successfully bring to market new test protocols; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
Posted by AGORACOM-JC
at 7:24 AM on Tuesday, December 8th, 2020
Initial sales, distribution agreements, filed patents and Government funding move BioCloud into the market
Set to ship its COVID-19 technology (“Kontrol BioCloud” or “BioCloud”) BioCloud, to customers and distributors around the world.
BioCloud is a real-time analyzer designed to detect airborne viruses, including SARS-COV-2, by continuously sampling air quality and triggering a silent, cloud-based alert to facility managers.
TORONTO , Dec. 8, 2020 – Kontrol Energy Corporation (“Kontrol” or the “Company”), a Canadian public Company (CSE: KNR) (OTCQB: KNRLF), is set to ship its COVID-19 technology (“Kontrol BioCloud” or “BioCloud”) BioCloud, to customers and distributors around the world. BioCloud is a real-time analyzer designed to detect airborne viruses, including SARS-COV-2, by continuously sampling air quality and triggering a silent, cloud-based alert to facility managers.
Initial contracts include sales with Kontrol customers and non-exclusive distribution and an exclusive distribution agreement for North America , Australia and New Zealand with United Safety and Survivability Corp.
Patents Filed On November 30th, 2020 the Company announced the filing of 4 patents for the BioCloud technology with 3 patents filed in the USA and 1 patent in Canada .
“The focus of our BioCloud technology is to help create safer spaces globally as we collectively continue to face the challenge of the COVID-19 pandemic,” says Paul Ghezzi , CEO Kontrol. “Initial deliveries are set to arrive to Kontrol customers and distributors in January 2021 . Our team has been working around the clock to launch BioCloud into the global market.”
Manufacturing With COVID-19 cases spiking globally and with increases anticipated into the winter season, BioCloud distribution plans are in high gear.
“We have the required local manufacturing capability to meet anticipated production volumes,” says Gary Saunders , VP of Kontrol. “We are pleased that the majority of our supply chain is Canadian.”
Kontrol has engaged OES Inc. a local design and contract manufacturer in London, Ontario to produce the BioCloud units. OES Inc. has a long and established history of assisting with the design and manufacturing of complex technology.
“Having BioCloud developed and now being produced in Ontario, Canada is very important to us,” continues Paul Ghezzi . “Our plans to have the initial production and supply chain sourced in Canada means that we are creating jobs while helping to solve the global pandemic that is COVID-19.”
“OES has the ability and capacity to ramp up to meet the required BioCloud manufacturing requirements and we can also scale with BioCloud as required,” says Jeff Stewart , President OES Inc. “We are committed to supporting local jobs, growth and Ontario exports.”
Kontrol receives additional federal funding On December 3rd, 2020 the Company announced that it had received advisory services and additional $500,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) .
“This is another important accomplishment and milestone for Kontrol and represents the continuing advancement of the BioCloud technology,” continues Paul Ghezzi . “We are grateful for and proud of this support from our federal government.”
Kontrol’s distribution agreement with United Safety and Survivability Corp Under the terms of the agreement, the exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America , Australia , and New Zealand . The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes.
Joseph Mirabile , CEO of United Safety stated, “United Safety and Survivability Corporation is committed to delivering the most innovative and reliable solutions that our customers trust to protect life and property. We are very excited to be sharing the Kontrol BioCloud technology with all of our customers. We see interest and demand for this innovative technology, which can help create safer spaces and help our customers solve many of the challenges they are facing in relation to the impact COVID-19 has on their business.”
Ongoing Service The patented and proprietary detection chamber is at the heart of BioCloud. The detection chamber is a consumable that needs to be replaced when it comes into contact with the SARS- CoV-2 virus. Kontrol is launching a new service to assist customers with the disposal and recycling of BioCloud’s propriety detection chamber.
The service allows for customers to return and recycle the detection chamber and receive a discount on future purchases of consumable detection chambers.
“This new service is a win-win as Kontrol is able to recycle various materials and customers are able to receive a discount on future purchases of the BioCloud consumables,” continues Gary Saunders .
Purchase The Company estimates a $12,000 USD per unit sale price for BioCloud based on current supply chain components. However, the Company offers volume discounts for aggregate purchases and further, the Company will offer a financing plan should customers require it.
About Kontrol BioCloud BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.
Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com
BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.
About Kontrol Energy Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 9:26 PM on Monday, December 7th, 2020
Binovi Technologies (VISN:TSXV) is a Vision Therapy and Training Company that goes well beyond fixing eyes that simply can’t read letters on an eye chart. That’s what your optometrist does when they prescribe glasses.
What Binovi does is far more exciting and ground-breaking. Without getting scientific, Binovi delivers higher performing brains by optimizing the performance of your eyes. The result is a faster brain through stronger eyes, which creates quite the edge for the world’s best athletes and explains why their client list includes:
Dallas Stars (NHL)
Chicago Cubs (MLB)
Sporting KC (MLS)
Tennis Canada
Showcased During NFL Scouting Combine
Eli Wilson Goaltending – The World Leader In Hockey Goaltending Development
BINOVI HAS ALREADY GONE GLOBAL
Since the launch of its Binovi state-of-the-art flagship, more than 800 organizations have been registered and have used the platform for vision therapy, sports vision performance. These organizations have created nearly 31,000 users, together completing more than 400,000 active sessions.
BINOVI CONNECT TAKES THE COMPANY INTO GLOBAL HOMES
The Company’s new web-based video conferencing app goes even further by providing remote telehealth capabilities. Binovi Connect allows VISN to compete and offer care in any market in the world, hyper-scaling its growth through the optimization of its provider network of over 800 registered providers, and facilitating care to individuals from the classroom or the comfort of home. Binovi Connect enables users to connect with vision care professionals focused on concussion, reading skills, athletic enhancement and more.
Turn off NetFlix. ignore your social media notifications. Grab your favourite beverage, call a couple of friends and watch this interview with Binovi CEO, Adam Cegielski / CEO
Can’t spare enough time to stare at a screen? Take AGORACOM with you in your car or on your walk by Podcast on Apple, Google, Spotify or your favourite podcaster.
Posted by AGORACOM-JC
at 5:54 PM on Monday, December 7th, 2020
There is no denying the world of esports was already on a rapid growth rate prior to the COVID-19 pandemic. However, according to TGS Esports (TGS:TSXV), the growth and awareness of esports over the past several months has accelerated the industry by at least a couple of years, if not more.
Recognizing this trend, TGS pivoted quickly from venue based esports to becoming a leader in esports events, sponsorship and productions. More than just lip service, tournaments hosted to date have been sponsored by the likes of:
Pepsi
Red Bull
7-11
Shaw Cable
More than just events, TGS also creates high quality production value out of these events, which have already seen more than 20,000 hours of viewership on Twitch and featured on GINX Esports TV (Canada), with the potential to expand with GINX to over 50 countries.
If the story ended there, TGS would have the makings of a great early stage esports story …. but it doesn’t
$6 MILLION ACQUISITION OF “PEPPER ESPORTS”
The recent acquisition of Pepper Esports takes the TGS offering to a whole different level by providing everyone from enterprise sized clients to small business to a group of buddies to create their own esports tournaments. The platform is so powerful it will handle everything from registration to game play, prize payouts and everything in between that an entity needs to host a successful esports tournament.
Awesome right? No, it gets better.
Hosting your own esports tournament is FREE. TGS and Pepper figured out that the best way to get mass usage of their platform is to make it $0 upfront and generate $$ from revenue share on all transactions that take place during the tournament.
When you bolt on the fact that TGS can now broadcast that tournament, the Company believes its offering can’t be matched anywhere in the world.
We like it so much that we’re already considering hosting Agoracom esports tournaments for clients and shareholders who can either play or watch.
Why? Volcanic was founded in 2018 and is the creator of the National Esports Scholastic League, a first of its kind initiative that works directly with school districts and educators to create various esports initiatives. To date Volcanic has worked with over 1000 high school students in 13 different cities spanning 6 school districts.
With 30% of kids under 18 playing esports right now – and many of them unable to play physical sports – the growth of high school esports is where you want to be.
Why? CEO Khouri stated “At TGS we are working with creators on a daily basis. One constant we have dealt with is that creators love creating but may not have the experience with brand deals or legal matters” said Spiro Khouri , co-founder and CEO of TGS. “We’re helping creators legitimize their career path and guiding them through that process. At the same time, we’re able to connect our partner brands with creators to create mutually beneficial relationships.”
With 7,000,000 esports streamers on Twitch right now, TGS is pretty confident in its ability to match the right creators with the right brands, which only serves to further strengthen their ecosystem.
Watch this great interview with the CEO Spiro Khouri to find out how TGS is planning to play a major role in the growth of esports this decade.
Posted by AGORACOM-JC
at 5:38 PM on Monday, December 7th, 2020
Entered a binding share purchase agreement to acquire a private entity VERA TM (Visual Efficiency RAting), its related patents, associated intellectual property, and available inventory, to further expand the company’s vision technology stack as it continues to execute upon its global commercialization strategy.
The transaction will further strengthen the company’s acquisition history, representing continuous investment growth within human performance software and technology.
Toronto, New York –December 7, 2020 –Binovi Technologies Corp., (Binovi) (TSXV:VISN)|(OTC:BNVIF)|(GR:2EYA) , a leader in vision performance technology, announces that, subject to the approval of the TSX Venture Exchange, it has entered a binding share purchase agreement to acquire a private entity VERA TM (Visual Efficiency RAting), its related patents, associated intellectual property, and available inventory, to further expand the company’s vision technology stack as it continues to execute upon its global commercialization strategy. The transaction will further strengthen the company’s acquisition history, representing continuous investment growth within human performance software and technology.
“We’re cornering the market on what’s available and possible with remote vision screening technology, and bringing a proven, scalable solution to our users and future users through Binovi. By baselining and screening potential patients and clients early, quickly, and easily, we’re able to help those people seek the vision care that they may unknowingly need, one of Binovi’s longstanding foundational goals,” stated Adam Cegielski, Binovi Chief Executive Officer.
Developed for eye doctors, educators, and school nurses, VERA offers a much-needed, simple, and validated national standard for school vision screening that goes beyond visual acuity or eyesight; It identifies students with vision difficulties related to classroom and independent learning, such as focusing issues, eye-teaming and eye-tracking problems, and provides a clear point of referral to a vision professional. It is anticipated to be highly impactful in an educational context for differentiating vision issues versus special needs cases, reducing the burden of special education costs.
“It is very gratifying that VERA’s unique vision screening methods will have more widespread benefits as part of Binovi’s technology-driven vision remediation platforms. We can all look forward to many more students with learning-related vision problems being identified and enjoying the rewards of timely and appropriate interventions,” commented Dr. Stephen Galanter, VERA Founder.
VERA is the first program to address the substantial personal, educational, and monetary costs associated with ineffective school vision screening by providing a superior, standardized testing method and automated reporting of test results .
– Up to 25% of students in grades K-12 have visual problems that can impede learning, according to the American Public Health Association – The Vision Council of America estimates that up to 50% of learning-disabled children have undiagnosed vision problems.
A paradigm shift in identifying persons who escape detection on routine vision screenings, VERA utilizes evidence-based, standardized, published, and reliable tests to capture patients with tracking, focusing, and eye teaming problems who may benefit from visual interventions. Its age-related scoring mechanism is driven by an extensive database and results are independent of IQ, socioeconomic status, and curriculum-based assessments, making it a valuable adjunct in educational settings. The current iteration includes a research-backed normative data set for measuring individual performance.
“It is archaic that we continue to rely on visual screening measures such as visual acuity that were developed in the 1800s. VERA incorporates procedures that have much greater bearing on a child’s performance in a technology-driven world, ” commented Dr. Leonard Press, Binovi Chief Scientific Officer.
VERA’s technology will integrate into the company’s Binovi product platform. With the recent announcement and launch of Binovi Connect, the VERA acquisition and integration provides Binovi an additional tool set to expand its offering through the ability to baseline/train/enhance performance of the visual system. With the current post-COVID drive in education and healthcare toward remote learning and telehealth, this will complement a hybrid model that blends elements of at-home and in-person care. This will allow deployment via web browser or iOS/Android and paves the way for remote controlling screening.
“We’re delighted to be able to add a simple, validated screening tool to the Binovi Platform, and use the VERA datasets to validate both the Binovi hardware and software tools as well as a point of comparison for our existing user results. Together, this new screening process will be a great fit for the verticals we’re targeting with Binovi,” commented Sam Mithani PhD, Binovi Chief Technology Officer.
As consideration for the acquisition, Binovi will issue an aggregate of 13.390 million common shares, equivalent to approximately $3.350-million (CAD), at a deemed price of 25 Canadian cents to the shareholders of the private entity VERA, subject to the approval of the TSX Venture Exchange.
In connection with the completion of the Transaction, the Company will issue 267,800 common shares to an arms-length third-party who assisted with facilitating the Transaction.
About VERA (Visual Efficiency RAting)
VERA™ is a two-part vision screening program designed for school heath, occupational therapy and special education settings. VERA’s school health component identifies more students with common vision difficulties and generates referral letters to eye doctors and parents and demographic reports for school nurses and administration. The program can generate grade-specific lists of students with vision difficulties for teachers to better accommodate these students in class and reinforce the vision referral to parents. Through these reports and letters and by automated follow-up on unfulfilled vision referrals, VERA identifies vision issues and promotes timely vision care.
VERA’s unique “visual efficiency” screening component allows occupational therapists and special educators to rate focusing, eye-teaming and eye tracking abilities which are crucial to attentive reading and learning. Strategies are also provided to support these identified students. VERA is easy to run with no previous clinical training. Tests are straightforward with helpful instruction screens and alerts guard against invalid testing and false positives.
VERA has been patented and program components have been tested on over a million students. https://visualscreening.com/
About Binovi Technologies Corp.
Binovi is a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 1,500 locations across 20 countries.
Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com. The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 4:50 PM on Monday, December 7th, 2020
Earlier today, MTRX announced its “Uplist Plan” outlining its proposed plan to: 1. Apply for uplisting to the Toronto Stock Exchange (“TSX”), as a technology company, from the TSX Venture Exchange (“TSXV”).
2. Secondly, if the Company is successful in uplisting to the TSX, Loop ‘s intention to then begin the process of filing with the Securities and Exchange Commission of the United States (the “SEC”) to apply to be listed on the NASDAQ.UPLIST PLAN ENACTED IN ANTICIPATION OF COMPANY GROWTH IN 2021
2020 has seen extraordinary growth for the Company in terms of – most importantly – the growth of the Company’s sales pipeline. Though Loop cannot provide any assurances as to the success stemming from its current and growing sales pipeline, CEO Robert Anson is of the strong opinion that MTRX will continue to see increased demand in the marketplace for its AI data applications and product service as a result of the digital transformation driven by COVID-19. To this end, CEO Anson stated:
“As a result of our immutable relevancy, high demand for Loop’s products, pipeline growth, and ability to easily scale into a global marketplace that is in full press digital transformation, we expect a continued accelerated pace that now warrants an uplist and dual list strategy that will attract institutional investors commensurate with our anticipated profile in 2021 and far beyond.”
Watch our powerful interview with Loop Insights CEO Robert Anson.
